Citadel Advisors
TSHA icon

Citadel Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Citadel Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$211K Buy
47,200
+27,600
+141% +$128K ﹤0.01% 11309
2025
Q4 		$108K Buy
+19,600
New +$95.2K ﹤0.01% 11572
2025
Q2 		– Sell
-5,500
Closed -$7.64K – 15149
2025
Q1 		$7.64K Buy
5,500
+3,700
+206% +$6.19K ﹤0.01% 13683
2024
Q4 		$3.11K Sell
1,800
-8,600
-83% -$17.8K ﹤0.01% 14025
2024
Q3 		$20.9K Sell
10,400
-5,500
-35% -$12.1K ﹤0.01% 12746
2024
Q2 		$35.6K Sell
15,900
-49,300
-76% -$143K ﹤0.01% 12103
2024
Q1 		$187K Buy
65,200
+35,900
+123% +$74.8K ﹤0.01% 10425
2023
Q4 		$51.9K Sell
29,300
-200
-0.7% -$399 ﹤0.01% 11748
2023
Q3 		$93.2K Buy
29,500
+28,000
+1,867% +$52.3K ﹤0.01% 10990
2023
Q2 		$992 Sell
1,500
-300
-17% -$217 ﹤0.01% 14004
2023
Q1 		$1.44K Sell
1,800
-47,500
-96% -$61.4K ﹤0.01% 14299
2022
Q4 		$111K Sell
49,300
-33,100
-40% -$67K ﹤0.01% 11064
2022
Q3 		$159K Buy
82,400
+59,400
+258% +$216K ﹤0.01% 10644
2022
Q2 		$86K Buy
23,000
+6,400
+39% +$25.4K ﹤0.01% 11541
2022
Q1 		$108K Buy
+16,600
New +$124K ﹤0.01% 12214

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's TSHA Position: Q1 2026 in Review

Citadel Advisors reduced its Taysha Gene Therapies (TSHA) stake by 78% in Q1 2026, selling an estimated $6.71M and leaving 411,135 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #6255.

Citadel Advisors first reported a position in TSHA in Q3 2020 and has held it in 19 quarters since. The position peaked at $10.2M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Citadel Advisors held 411,135 shares of Taysha Gene Therapies worth $1.84M as of Q1 2026.
  • Citadel Advisors sold 1,443,720 Taysha Gene Therapies shares in Q1 2026, an estimated $6.71M.
  • Taysha Gene Therapies made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6255 holding.
  • Citadel Advisors first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 19 quarters since.
  • Citadel Advisors's Taysha Gene Therapies position peaked at $10.2M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.